ARCUS BIOSCIENCES, INC.

Estimates Revisions Arcus Biosciences, Inc.

Equities

RCUS

US03969F1093

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 21:00:02 04/10/2024 BST			5-day change	1st Jan Change
16.65 ^USD	+8.75%		+8.05%	-12.83%

10-02	Arcus Biosciences, AstraZeneca Collaborate on Developing Carcinoma Treatment	MT
10-02	Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Cas Datifan in Combination with Volrustomig in Renal Cell Carcinoma	CI

Turnover - Evolution of Analysts' Estimates

Earnings Per Share (EPS) - Evolution of Analysts' Estimates

EBIT - Evolution of Analysts' Estimates

Dividend / Share (DPS) - Evolution of Analysts' Estimates

Cash or Net Debt - Evolution of Analysts' Estimates

Sector Comparison:

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	1m. EPS revision	1m. Revenue rev.	1y. EPS revision	1y. Revenue rev.
	ARCUS BIOSCIENCES, INC.
	LONZA GROUP AG
	IQVIA HOLDINGS INC.
	ALNYLAM PHARMACEUTICALS, INC.
	CELLTRION, INC.
	ICON PUBLIC LIMITED COMPANY
	MODERNA, INC.
	UNITED THERAPEUTICS CORPORATION
	BIO-TECHNE CORPORATION
	MEDPACE HOLDINGS, INC.
	Average
	Weighted average by Cap.

See all sector revisions

Turnover

Estimates Revisions:

Earnings Per Share (EPS)

Estimates Revisions:

EBIT

Estimates Revisions:

Dividend / Share (DPS)

Estimates Revisions:

Cash or Net Debt

Estimates Revisions:

+39.41% on our US portfolio vs. 25.67% on the S&P 500 net Total Return

Replicate our performance

Replicate our performance